By 2007, Clinical Trials Were Beginning to Show Cannabinoids Help With MS Pain and Spasticity
After years of conflicting results, the majority of clinical trials were converging on the finding that cannabinoids benefit at least a subset of MS patients for pain and spasticity.
Quick Facts
What This Study Found
This review surveyed the rapidly expanding clinical trial landscape for cannabinoids in multiple sclerosis, covering THC, dronabinol, Sativex (THC:CBD), CT-3, nabilone, and other cannabis extracts.
The author noted a shift from earlier conflicting evidence to emerging consensus: the majority of recent studies suggested cannabinoids were useful for at least some MS patients with pain and spasticity. The adverse side effect profile was generally described as mild compared to other drugs used for these symptoms.
However, two concerns remained: potential long-term psychiatric side effects and effects on fetal development. The review emphasized that the field was moving from whether cannabinoids work in MS to identifying which patients benefit most and optimizing formulations.
Key Numbers
Multiple cannabinoid formulations reviewed: THC, dronabinol, Sativex (THC:CBD), CT-3, nabilone. Multiple clinical trials surveyed. Side effects generally rated as mild compared to alternatives.
How They Did This
Narrative review of recent clinical trials investigating cannabinoids for MS symptom management. The author compared findings across different cannabinoid formulations, study designs, and outcome measures.
Why This Research Matters
This review captured a turning point in the field: by 2007, the evidence had shifted from uncertain to generally supportive of cannabinoids for MS symptoms. This consensus eventually led to regulatory approvals.
The Bigger Picture
The gradual consensus described in this review ultimately supported the approval of Sativex in over 25 countries for MS-related spasticity. The question shifted from "do cannabinoids work?" to "for whom and how best?"
What This Study Doesn't Tell Us
As a narrative review, it did not formally assess bias or evidence quality across studies. The "subset of individuals" who benefit was not well characterized. Long-term safety data remained limited.
Questions This Raises
- ?Which MS patients respond best to cannabinoid therapy?
- ?What are the long-term psychiatric risks of sustained cannabinoid use in MS patients?
Trust & Context
- Key Stat:
- Majority of clinical trials showed cannabinoids benefit a subset of MS patients
- Evidence Grade:
- This is a narrative review synthesizing clinical trial evidence. While it reflects a growing consensus, it does not apply systematic review methodology.
- Study Age:
- Published in 2007. The evidence base has expanded substantially since then, and Sativex has been approved in over 25 countries for MS spasticity.
- Original Title:
- Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.
- Published In:
- Expert review of neurotherapeutics, 7(9), 1157-63 (2007)
- Authors:
- Smith, Paul F(5)
- Database ID:
- RTHC-00293
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which cannabinoid formulation works best for MS?
As of this review, Sativex (THC:CBD mouth spray) had the strongest clinical trial support. Different formulations showed varying efficacy, suggesting the specific composition and delivery method matter significantly.
Why do only some MS patients benefit?
The review didn't fully explain this. Possible factors include the type and location of MS lesions, individual endocannabinoid system differences, and the specific symptoms being targeted. Identifying predictors of response remains an active research area.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00293APA
Smith, Paul F. (2007). Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.. Expert review of neurotherapeutics, 7(9), 1157-63.
MLA
Smith, Paul F. "Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.." Expert review of neurotherapeutics, 2007.
RethinkTHC
RethinkTHC Research Database. "Symptomatic treatment of multiple sclerosis using cannabinoi..." RTHC-00293. Retrieved from https://rethinkthc.com/research/smith-2007-symptomatic-treatment-of-multiple
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.